Between 2002 and 2016, 153 VS were treated in 153 patients. 116(76%) VS received LB-SRS and 37(24%) CK-SRS. Male/female ratio was 70/83. Median age was 60y (range,20-84). Median prescribed dose was 14Gy (range, 12-20). Median tumor diameter was 5mm (range,0.2-23). SRS was performed as salvage therapy for recurrent or progressive tumors in 36(23%) patients already submitted to total or subtotal resection (10-28% and 26-72%, respectively). The other 117(77%) patients underwent SRS alone. 25(16%), 61(40%), 52(34%) and 15(10%) VS were classified as Koos tumor grade I, II, III and IV, respectively. 147(96%) patients had hearing loss as an initial symptom, of which 73 (48%) with “non-serviceable” hearing function. Trigeminal neuralgia and facial pain/paraesthesia were presenting symptoms in 9(6%) and 27(17%) patients, respectively. At a median follow-up of 6 years(range,3–16), 32(21%)patients had an objective improvement of their initial symptoms, 94(61%) stable symptoms, and 27(18%) worsened their pre-treatment symptoms. Only in 2(1%) cases MRI showed progression of VS. Crude radiologic TC rate was 99%. TC was not conditioned by tumour volume, prescribed dose (≤14Gy vs >14Gy), Koos tumor class (I+II vs III+IV) and/or previous surgery. Among patients with “serviceable-hearing” (80-52%), 54(67%) maintained their functional hearing score, 15(19%) improved and 11(14%) worsened. Median tumor size in “serviceable-hearing” patients was 5mm (range, 0,2-30) and median dose administered was 14Gy (range, 12-17,5). No statistically significant difference was found with regard to tumor size (≤5mm vs>5mm) and prescribed dose (≥14 Gy vs<14 Gy).5 of 126(4%) patients without pre-SRS facial toxicity, developed incomplete facial nerve palsy, that regressed in a median time of 6 months. 15 of 144(10%) patients without pre-SRS trigeminal neuralgia developed trigeminal toxicity which was transient or stable/mild during follow-up in 13 (8.5%) patients. In only 2(1%) cases trigeminal toxicity was severe and appeared at a median time of 12 months. Late toxicity was significantly correlated to tumor size (≤5mm vs >5mm) (p=0.05). Prescribed dose and Koos tumor grade (I+II vs III+IV) not showed a statistically significant.